Presentations
2023 – 16th Clinical Trials in Alzheimer’s Disease Conference Oral Presentation, Boston, MA – LB03 – ‘Topline Results From the Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed With Mild-to-Moderate Alzheimer’s Disease. – Download pdf
2022 – Alzheimer’s Association International Conference. Poster Presentation, San Diego, CA – “Towards a more representative Alzheimer’s disease clinical trial: Ethnic differences in underlying pathology call for demographic consideration in drug label development”. – Download pdf
2022 – Alzheimer’s Association International Conference. Poster Presentation, San Diego, CA – “ The PIONEER Study: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial of the Effects of T3D-959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer’s Disease Subjects: Study Update”. – Download pdf
2022 – Alzheimer’s Association International Conference. Oral Presentation, San Diego, CA – “Drug Development Approach and Mechanism of Action of T3D-959” – Download pdf
2022 – Alzheimer’s Association International Conference. News Briefing, San Diego, CA – “ Preliminary Safety and Efficacy Results from the Phase 2 PIONEER Trial of T3D-959 in Mild to Moderate Alzheimer’s Patients” – Download pdf
2022 – AD/PD 2022, International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. Oral Presentation, Barcelona, Spain – ‘PIONEER, a Phase 2 Study to Evaluate Treatment with T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease: Study Design and Update’ – Download pdf
2021 – 14th Clinical Trials in Alzheimer’s Disease Conference Oral Presentation, Boston, MA – OC22 – ‘PIONEER, a Phase 2 Study to Evaluate Treatment with T3D-959 in Patients with Mild to Moderate Alzheimer’s Disease: Study Design and Update’ – Download pdf
2020 – Alzheimer’s Association International Conference Oral Presentation – ‘A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial of the Effects of T3D-959 on Safety, Cognition, Function and Plasma Biomarkers in Mild to Moderate Alzheimer’s Disease Subjects: Rationale and Study Design’ – Download pdf
2018 – Didsbury J, Gabriel H, Strittmatter W and Chamberlain S (2018) A Neurometabolic Approach to Treating Alzheimer’s Disease: Hypothesis Testing in a Phase 2a Exploratory Clinical Trial with the New Chemical Entity T3D-959. Neurotherapeutics (2018) 15:819 – Download pdf
2018 – Alzheimer’s Association International Conference Oral Presentation, Chicago, IL – ‘Effects of a PPAR Delta/Gamma Agonist, T3D-959, on Metabolic and Cognitive Functions in Mild to Moderate Alzheimer’s Disease Subjects. – Download pdf
2018 – 20th Annual American Society for Experimental Neurotherapeutics Oral and Poster Presentation, Washington, DC – A Neurometabolic Approach to Treating Alzheimer’s Disease: Hypothesis Testing in a Phase 2a Exploratory Clinical Trial with the New Chemical Entity T3D-959. – Download pdf
2016 – 9th Clinical Trials in Alzheimer’s Disease Conference Oral Presentation, San Diego, CA – OC39 – Cognitive Improvement in Mild to Moderate Alzheimer’s Patients: Final Results of an Open Label, Phase 2A Study of T3D-959 – Download PDF
2016 – Alzheimer’s Association International Conference Poster Presentation Toronto – Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated with T3D-959: Interim Results of a Phase 2a Open Label Clinical Trial – Download PDF
Publications:
2020 – Chamberlain S, Gabriel H, Strittmatter S, Didsbury J (2020) An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer’s Disease. J Alzheimer’s Dis. 73:1085-1103. – Download PDF
2017 – De la Monte SM, Tong M, Didsbury J (2017) Improved Brain Insulin/IGF Signaling and Decreased Neuro-inflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer’s Disease. J Alzheimers Dis. 55:849-864. – https://www.ncbi.nlm.nih.gov/pubmed/27802237
2016 – Tong M, DeochandC, Didsbury J, de la Monte SM (2016) T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease. J Alzheimers Dis 51, 123-138. – https://www.ncbi.nlm.nih.gov/pubmed/26836193
2016 – Tong M, Dominguez C, Didsbury J, de la Monte SM. (2016) Targeting Alzheimer’s Disease Neuro-metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism 6:238. doi: 10.4172/2161-0460.1000238 – Download PDF
Videos:
2015 – CED Life Science Conference 2015 Showcase Oral Presentation, Raleigh, NC – View Video
2018 – Neurology Live interviews.
https://www.neurologylive.com/conferences/aaic-2018/john-didsbury-phd-going-against-the-grain-in-established-alzheimer
https://www.neurologylive.com/conferences/aaic-2018/john-didsbury-phase-iia-trial-t3d959-mild-moderate-alzheimer-disease